Trinidad Montero-Melendez

Summary

Affiliation: Queen Mary
Location: London, UK

Publications

  1. Vieites J, de la Torre R, Ortega M, Montero T, Peco J, Sánchez Pozo A, et al. Characterization of human cd200 glycoprotein receptor gene located on chromosome 3q12-13. Gene. 2003;311:99-104 pubmed
    ..By RT-PCR, we have analyzed the expression of the four transcript variants in human placenta, spleen, liver, brain and kidney. ..
  2. Patel H, Leoni G, Melendez T, Sampaio A, Perretti M. Melanocortin control of cell trafficking in vascular inflammation. Adv Exp Med Biol. 2010;681:88-106 pubmed publisher
  3. Montero Melendez T, Patel H, Perretti M. Role of melanocortin receptors in the regulation of gouty inflammation. Curr Rheumatol Rep. 2011;13:138-45 pubmed publisher
  4. de Lima C, Tamura E, Montero Melendez T, Palermo Neto J, Perretti M, Markus R, et al. Actions of translocator protein ligands on neutrophil adhesion and motility induced by G-protein coupled receptor signaling. Biochem Biophys Res Commun. 2012;417:918-23 pubmed publisher
    ..Taken together, these data highlight TSPO as a modulator of pathways of neutrophil adhesion and locomotion induced by GPCR, connecting TSPO actions and the onset of an innate inflammatory response. ..
  5. Dalli J, Montero Melendez T, McArthur S, Perretti M. Annexin A1 N-terminal derived Peptide ac2-26 exerts chemokinetic effects on human neutrophils. Front Pharmacol. 2012;3:28 pubmed publisher
    ..We postulate that the generation of Annexin A1 N-terminal peptides at the site of inflammation may expedite the egress of migrated leukocytes thus promoting the return to homeostasis. ..
  6. Patel H, Montero Melendez T, Greco K, Perretti M. Melanocortin receptors as novel effectors of macrophage responses in inflammation. Front Immunol. 2011;2:41 pubmed publisher
    ..The overall outcome will be identification of selective MC agonists as a strategy for innovative anti-inflammatory therapeutics. ..
  7. Renshaw D, Montero Melendez T, Dalli J, Kamal A, Brancaleone V, D Acquisto F, et al. Downstream gene activation of the receptor ALX by the agonist annexin A1. PLoS ONE. 2010;5: pubmed publisher
    ..We believe these new data raise the profile of AnxA1 from being solely a short-term anti-inflammatory factor, to being a 'trigger' of the endogenous pro-resolution arsenal. ..
  8. Montero Melendez T, Patel H, Seed M, Nielsen S, Jonassen T, Perretti M. The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties. Am J Pathol. 2011;179:259-69 pubmed publisher
    ..These findings might clarify the tissue-protective properties of AP214 in clinical settings and may open further development for novel MC agonists. ..
  9. Vessillier S, Adams G, Montero Melendez T, Jones R, Seed M, Perretti M, et al. Molecular engineering of short half-life small peptides (VIP, ?MSH and ??MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics. Ann Rheum Dis. 2012;71:143-9 pubmed publisher
    ..This platform delivery can be developed to control human arthritides and other autoimmune diseases. ..

Collaborators

Detail Information

Publications14

  1. Schutters K, Kusters D, Chatrou M, Montero Melendez T, Donners M, Deckers N, et al. Cell surface-expressed phosphatidylserine as therapeutic target to enhance phagocytosis of apoptotic cells. Cell Death Differ. 2013;20:49-56 pubmed publisher
    ..We conclude that targeting cell surface-expressed PS is an attractive strategy for treatment of inflammatory diseases and that the rationally designed RGD-anxA5 is a promising therapeutic agent. ..
  2. Montero Melendez T, Dalli J, Perretti M. Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors. Cell Death Differ. 2013;20:567-75 pubmed publisher
    ..We propose non-genomic modulation of AnxA1 in immune cells as a novel mechanism of action for HDACIs, which may underlie their reported efficacy in models of chronic inflammatory pathologies. ..
  3. Al Kashi A, Montero Melendez T, Moradi Bidhendi N, Gilligan J, Mehta N, Perretti M. The calcitonin and glucocorticoids combination: mechanistic insights into their class-effect synergy in experimental arthritis. PLoS ONE. 2013;8:e54299 pubmed publisher
    ..Substantial GC dose reduction, together with the absence of exacerbated adverse effects, indicated a significant clinical potential for this co-therapy in RA and beyond. ..
  4. Rhodes D, Pini M, Castellanos K, Montero Melendez T, Cooper D, Perretti M, et al. Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function. Obesity (Silver Spring). 2013;21:310-9 pubmed publisher
    ..Obesity leads to differential modulation of Gal-1, 3, 9 and 12 in VAT and SAT, with Gal-1 acting as a modulator of adiposity. ..
  5. Montero Melendez T, Forfar R, Cook J, Jerman J, Taylor D, Perretti M. Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3. Cell Mol Life Sci. 2017;74:1335-1345 pubmed publisher
    ..In addition, MC3 PAMs emerged as a viable approach to the development of innovative therapeutics for joint diseases. ..